Filament Health, NeoLumina Partner to Trial Psilocybin Drug for Eating Disorders

Filament is set to receive up to "seven figures" in milestone payments.

Clinical-stage psychedelic drug developer Filament Health Corp. (OTCQB: FLHLF) is teaming up with NeoLumina Bioscience Inc. to help test a psilocybin-based drug for eating disorders, the company said Friday.

The licensing agreement allows NeoLumina to use Filament’s proprietary botanical psilocybin drug candidate, PEX010, for its clinical and commercial development to address eating disorders.

PEX010, which is orally administered, received authorization from both the U.S. Food and Drug Administration and Health Canada to commence phase 1 and phase 2 human clinical trials.

“Nearly 10% of the global population suffers from an eating disorder and there are no approved drugs for most types,” NeoLumina CEO Gaetano Morello said in a statement.

NeoLumina is a life sciences company looking to develop “better first-line therapeutic candidates for mental health conditions that are based on psychedelic molecules,” the company said. The licensing agreement provides NeoLumina exclusive use of PEX010 for eating disorders. Additionally, the agreement stipulates that Filament will supply PEX010 to NeoLumina for research.

Under the terms of the contract, Filament is set to receive up to “seven figures” in milestone payments during NeoLumina’s clinical development phase and marketing authorization process. Future commercial royalties up to a low double-digit percentage of net sales are also included in the deal.

NeoLumina joins an expanding roster of Filament’s licensing partners, all utilizing PEX010 to further their clinical trial programs. Current partners are engaged in studies for conditions including opioid tapering, palliative care and alcohol use disorder.

Adam Jackson

Adam Jackson writes about the cannabis industry for the Green Market Report. He previously covered the Missouri Statehouse for the Columbia Missourian and has written for the Missouri Independent. He most recently covered retail, restaurants and other consumer companies for Bloomberg Business News. You can find him on Twitter at @adam_sjackson and email him at adam.jackson@crain.com.


Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.